Ocugen 2026: Revenue $1.95M, EPS ($0.01) — 10-Q Summary

What happened

Ocugen reported 2026 revenue of $1.95 million, up 11.4% from a year earlier, and a net loss of $3.6 million versus $20.05 million previously. Diluted loss per share improved to $0.01 from $0.07. The company also reported clinical-trial progress and expected future results and regulatory submissions.

Confirmed

Global impact / market context

Higher revenue and a narrower net loss indicate improved reported results, but revenue remains small relative to the stated loss. Continued clinical development investment means Ocugen still needs funding for trials, while future results and regulatory submissions could influence whether its programs advance toward potential revenue.

Analyst inference

The article describes a clinical-stage company whose financial update sits alongside milestones rather than established product sales. Collaboration revenue rose about 8% to $5.0 million for the first nine months, while Ocugen expects continued development spending, so trial costs and progress both matter to its financial outlook.

Analyst inference

What to watch

1. Watch for OCU400 topline results expected in the first quarter of 2027; the article says its Phase 3 trial completed enrollment with 140 participants. Confirmed
2. Track OCU410ST topline results expected in the second quarter of 2027 and the planned mid-2027 BLA submission, a request for regulatory approval to market a biologic. Proposed
3. Compare future collaboration revenue with clinical-development spending: if costs continue while revenue remains limited, Ocugen could need additional funding to sustain its trials. Analyst inference

Evidence

• Original source link unavailable